CTI BioPharma Corp. (CTIC)
(Delayed Data from NSDQ)
$0.99 USD
+0.01 (1.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.99 USD
+0.01 (1.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -6.58% and 17.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
by Zacks Equity Research
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy CTI BioPharma (CTIC) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
by Zacks Equity Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Implied Volatility Surging for CTI BioPharma (CTIC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study
by Zacks Equity Research
CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?
by Zacks Equity Research
Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.04% and 104.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
by Zacks Equity Research
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
by Zacks Equity Research
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.